Plain-English translation of NCT07318129 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
iPROACT-MS is testing whether indole-3-propionic acid (IPA)—a natural substance your gut bacteria normally produce—can help people with relapsing-remitting multiple sclerosis (RRMS). Researchers believe this medication may reduce MS disease activity, protect your nerves from damage, and improve metabolic health. Half of participants will receive the actual treatment while the other half receives a placebo (inactive pill) to fairly compare results.
Multiple sclerosis causes the immune system to attack nerve cells, leading to relapses, disability, and nerve damage. Current treatments help, but researchers are looking for additional ways to reduce inflammation and protect nerve health—this medication may offer a new approach by working through your gut bacteria.
You likely qualify if…
You likely don't qualify if…
You will take a daily capsule containing either the medication or a placebo for the duration of the study. You'll have regular clinic visits for monitoring, blood tests, and MRI scans to measure your MS disease activity and track changes in your health. Researchers will also ask about your lifestyle, diet, and overall well-being to understand how the treatment affects different aspects of your health.
AI-generated summary from trial data · Jun 25, 2026 · Not medical advice
Denmark